ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 11

Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC

, , ,
EP. 1: Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
EP. 2: Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
EP. 3: Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
EP. 4: Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
EP. 5: Exciting Data and Trials in Progress from ASCO 2024
EP. 6: Ongoing RCC Clinical Trials that may Impact Practice
EP. 7: Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
EP. 8: Dr Voss Application of Updated KEYNOTE-564 Data
EP. 9: Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
EP. 10: World Health Organization (WHO) Classification Updates for Papillary RCC
Now Viewing
EP. 11: Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
EP. 12: The Role of Chemotherapy in nccRCC Treatment
EP. 13: Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
EP. 14: Final Thoughts/Looking Forward

1. Please mention if there are any other recently published or pending data for treatment of patients with RCC beyond frontline therapy that you are looking forward to